AstraZeneca to take COVID-19 combo therapy into the clinic

10 June 2020

Complementing its pioneering work on a COVID-19 vaccine, British drugmaker AstraZeneca (LSE: AZN) has announced progress in the development of an antibody cocktail to treat infected people.

AstraZeneca has screened more than 1,500 antibodies for their ability to bind to the SARS-CoV-2 virus, and is now ready to test a combination of monoclonal antibodies in the prevention and treatment of COVID-19.

The firm has licensed six coronavirus-neutralizing antibodies from Vanderbilt University, in the USA, and has inked a deal with US government agencies to progress the pair of antibodies through to clinical testing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK